Biogen, perhaps the most international and certainly one of the most successful of the biotech specialist firms, is trying to graduate from a research corporation into a pharmaceutical manufacturer and marketer. Its recent public offering was designed to propel the company into this new stage by expanding its clinical testing program and building production facilities. With only one small-volume product on the market, and facing fierce competition from both the established pharmaceutical multinationals and the research-oriented gene splicing companies, Biogen struggles to position itself for the future.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Powledge, T. Biogen in Transition: From Research Specialist to Manufacturer. Nat Biotechnol 1, 398–405 (1983). https://doi.org/10.1038/nbt0783-398
Issue Date:
DOI: https://doi.org/10.1038/nbt0783-398